Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JS25 is a selective, covalent BTK inhibitor that deactivates BTK by chelating Tyr551, exhibiting an IC50 of 5.8 nM. It suppresses cancer cell proliferation, induces pronounced cell death, and enhances Burkitt's lymphoma murine xenograft model outcomes. Importantly, JS25 efficiently penetrates the blood-brain barrier.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | JS25 is a selective, covalent BTK inhibitor that deactivates BTK by chelating Tyr551, exhibiting an IC50 of 5.8 nM. It suppresses cancer cell proliferation, induces pronounced cell death, and enhances Burkitt's lymphoma murine xenograft model outcomes. Importantly, JS25 efficiently penetrates the blood-brain barrier. |
In vitro | The 3-Hydroxybutyric acid medium can interact with lipids (using DPPC monolayer modeling) and alter phase behavior at clinical concentrations. The 3-Hydroxybutyric acid solid also reduces the interfacial viscosity of the DPPC monolayer.[1] |
Molecular Weight | 524.59 |
Formula | C29H24N4O4S |
CAS No. | 2411771-95-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JS25 2411771-95-2 UCM 05194 JS 25 JS-25 UCM05194 inhibitor inhibit